Celcuity, Inc. $CELC Stake Boosted by New York State Common Retirement Fund

New York State Common Retirement Fund raised its holdings in shares of Celcuity, Inc. (NASDAQ:CELC) by 68.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,704 shares of the company’s stock after purchasing an additional 19,313 shares during the period. New York State Common Retirement Fund owned about 0.11% of Celcuity worth $2,357,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of CELC. Soleus Capital Management L.P. boosted its holdings in shares of Celcuity by 17.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after buying an additional 437,696 shares during the period. Eventide Asset Management LLC boosted its stake in Celcuity by 9.8% in the second quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock valued at $18,549,000 after acquiring an additional 123,774 shares during the period. Saturn V Capital Management LP grew its holdings in shares of Celcuity by 8.4% during the second quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock valued at $15,827,000 after purchasing an additional 91,843 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Celcuity by 27.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 768,796 shares of the company’s stock worth $10,263,000 after purchasing an additional 166,324 shares during the period. Finally, Captrust Financial Advisors lifted its holdings in shares of Celcuity by 2.3% in the 2nd quarter. Captrust Financial Advisors now owns 570,441 shares of the company’s stock worth $7,615,000 after purchasing an additional 12,838 shares during the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Richard E. Buller sold 3,900 shares of Celcuity stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $96.73, for a total transaction of $377,247.00. Following the transaction, the director directly owned 7,260 shares in the company, valued at approximately $702,259.80. This trade represents a 34.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David Dalvey sold 20,000 shares of the business’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the completion of the sale, the director directly owned 90,000 shares in the company, valued at $10,802,700. This represents a 18.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 26,900 shares of company stock valued at $3,094,917. 15.78% of the stock is currently owned by corporate insiders.

Celcuity Stock Up 2.4%

CELC stock opened at $106.75 on Monday. The firm’s 50-day moving average is $105.02 and its two-hundred day moving average is $75.88. The company has a market capitalization of $4.94 billion, a price-to-earnings ratio of -29.09 and a beta of 0.36. Celcuity, Inc. has a 52 week low of $7.57 and a 52 week high of $120.32. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.13. On average, analysts forecast that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on CELC. Jefferies Financial Group upped their price objective on Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. Craig Hallum upped their price target on shares of Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen downgraded shares of Celcuity from a “hold” rating to a “sell” rating in a research report on Sunday, October 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Finally, Needham & Company LLC set a $95.00 price target on shares of Celcuity in a research note on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Celcuity has an average rating of “Moderate Buy” and an average price target of $105.25.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.